A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Active, not recruiting · NCT01878617 · Registry updated 2025-11-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioma, medulloblastoma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2025-11-13 | NCT01878617 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| National Cancer Institute (NCI) | 3015 |
| St. Jude Children's Research Hospital | 169 |
23 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.